Chloroquine-analogues block anthrax protective antigen channels in steady-state and kinetic studies

Christoph Beitzinger1, Angelika Kronhardt1, Roland Benz2

  • 1Rudolf Virchow Center, Research Center for Experimental Biomedicine, University of Würzburg, Versbacher Straße 9, 97078 Würzburg, Germany.

Toxicology
|May 18, 2023
PubMed

Insights

This study reveals that certain quinoline compounds effectively block the anthrax toxin

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Bacillus anthracis secretes a tripartite toxin, a prototype A-B toxin.
  • Anthrax toxin comprises lethal factor (LF), edema factor (EF), and protective antigen (PA).
  • Protective antigen (PA) forms channels that translocate LF and EF into target cells.

Purpose of the Study:

  • Investigate the structure-function relationship of quinolines blocking the PA63 channel.
  • Determine the binding affinity and kinetics of quinoline analogues to the PA63 channel.
  • Explore the therapeutic potential of 4-aminoquinolines against anthrax toxin.

Main Methods:

  • Reconstitution of the PA63 channel in lipid membranes.
  • Titration assays to measure equilibrium dissociation constants (affinity).
  • Ligand-induced current noise measurements with fast Fourier transformation to determine binding kinetics.

Main Results:

  • PA63 channel can be reconstituted in lipid membranes and blocked by chloroquine and other quinolines.
  • Some quinoline analogues exhibit higher affinity to the PA63 channel than chloroquine.
  • On-rate constants for quinoline binding are rapid (~10^8 M^-1·s^-1) and structure-independent.
  • Off-rate constants vary significantly (4–160 s^-1) based on quinoline structure.

Conclusions:

  • The PA63 channel possesses a binding site for quinolines.
  • Detailed kinetics and affinity data provide insights into quinoline interactions with the PA63 channel.
  • 4-aminoquinolines show promise as potential therapeutic agents against anthrax toxin.

Related Concept Videos

Direct-Acting Cholinergic Agonists: Pharmacokinetics01:31

Direct-Acting Cholinergic Agonists: Pharmacokinetics

Direct-acting cholinergic agonists, such as synthetic choline esters and naturally occurring alkaloids, exert their effects by enhancing the actions of acetylcholine and stimulating the parasympathetic nervous system. Synthetic choline esters share structural similarities with acetylcholine. For example, they have a positively charged quaternary ammonium or onium group, contributing to their hydrophilic characteristics. As a result, they are poorly absorbed in the body through oral...
1.3K
Indirect-Acting Cholinergic Agonists: Mechanism of Action01:18

Indirect-Acting Cholinergic Agonists: Mechanism of Action

Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship01:29

Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship

Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
612
Indirect-Acting Cholinergic Agonists: Pharmacokinetics01:22

Indirect-Acting Cholinergic Agonists: Pharmacokinetics

Indirect-acting cholinergic agonists, or anticholinesterases, enhance the body's cholinergic activity by inhibiting acetylcholine's breakdown. They are categorized as reversible or irreversible agents based on their mechanism of action. They are further classified into short-acting, intermediate-acting, and long-acting agents based on their duration of action.
Reversible agents containing quaternary amines, such as neostigmine and edrophonium, are not easily absorbed orally because they...
1.0K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship01:29

Cholinergic Antagonists: Chemistry and Structure-Activity Relationship

Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K
Anticholinesterase Agents: Poisoning and Treatment01:26

Anticholinesterase Agents: Poisoning and Treatment

Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.     
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
932